IFF price target raised to $80 from $75 at Baird

Baird analyst Ghansham Panjabi raised the firm’s price target on IFF to $80 from $75 and keeps an Outperform rating on the shares. The firm said the risk/reward biased higher and while considerable fatigue exists as it relates to the post-DuPont Nutrition & Biosciences investment profile at IFF, confirmation that pockets of green shoots are becoming more apparent across the portfolio and a sequential improvement in the volume profile from 2Q to 3Q are notable positives.